title: One-year clinical outcome after coronary stenting of very small vessels using 2.25 mm sirolimus- and paclitaxel-eluting stents: a comparison between the RESEARCH and T-SEARCH registries.
abstract: BACKGROUND
  The efficacy of sirolimus-eluting stents (SES) compared to paclitaxel-eluting stents (PES) remains unknown. We evaluated the clinical outcomes after implantation of 2.25 mm diameter SES and PES.
  
  
  RESULTS
  PES have been used as the stent of choice for all percutaneous coronary interventions as part of the prospective Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-SEARCH) Registry. Ninety consecutive patients received at least one 2.25 mm PES (PES group), and were compared with 107 patients who received at least one 2.25 mm SES as part of the RESEARCH registry. The overall population presented high-risk characteristics commonly excluded from most studies. Populations were well-matched. There were 2 (2.2%) incidents of subacute stent thrombosis in the PES group (in a 2.25 mm stent), and none in the SES group. At one year, the cumulative incidence of major adverse cardiac events was 5.6% in the SES group, and 17.8% in the PES group (p = 0.007). After adjustments for other significant univariate variables, presentation with acute coronary syndrome (ACS) (adjusted OR 5.2 [95% CI 1.8-15.0], p = 0.002) and PES utilization (adjusted OR 3.7 [95% CI 1.3-10.5], p = 0.013) were found to be significant independent predictors of major adverse cardiac events (MACE).
  
  
  CONCLUSIONS
  In an unselected population treated for very small vessel disease, SES were associated with better 12-month clinical outcomes and the use of PES was identified as an independent predictor of adverse events.
authors.affiliation: Cardiac Catheterization Laboratory, Thoraxcenter, Erasmus Medical Center, Rotterdam, Kamer Z-120, Dr. Molewaterplein 40, Rotterdam, The Netherlands 3015 GD. gatoenholanda@yahoo.com.ar
authors.forename: Gastón A
authors.initials: GA
authors.lastname: Rodriguez-Granillo
authors.forename: Marco
authors.initials: M
authors.lastname: Valgimigli
authors.forename: Héctor M
authors.initials: HM
authors.lastname: Garcia-Garcia
authors.forename: Andrew T L
authors.initials: AT
authors.lastname: Ong
authors.forename: Jiro
authors.initials: J
authors.lastname: Aoki
authors.forename: Carlos A G
authors.initials: CA
authors.lastname: van Mieghem
authors.forename: Keiichi
authors.initials: K
authors.lastname: Tsuchida
authors.forename: Georgios
authors.initials: G
authors.lastname: Sianos
authors.forename: Eugene
authors.initials: E
authors.lastname: McFadden
authors.forename: Willem J
authors.initials: WJ
authors.lastname: van der Giessen
authors.forename: Ron
authors.initials: R
authors.lastname: van Domburg
authors.forename: Pim
authors.initials: P
authors.lastname: de Feyter
authors.forename: Patrick W
authors.initials: PW
authors.lastname: Serruys
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000295:instrumentation*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D020099:Coated Materials, Biocompatible; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000628:therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use*; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012042:Registries; D020123:Sirolimus / Q000627:therapeutic use*; D015607:Stents; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D020099:Coated Materials, Biocompatible; D007166:Immunosuppressive Agents; D017239:Paclitaxel; D020123:Sirolimus